The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid growing market focus on corporate resilience, Abbott and ManpowerGroup delivered robust Q2 2026 financial results that exceeded expectations. Abbott reported a 13% surge in sales and subsequently raised its full-year adjusted EPS guidance to a range of $5.45 to $5.60. Simultaneously, ManpowerGroup posted revenues of $4.9 billion, marking an 8% increase driven by sustained hiring demand across the United States and Latin America.
Sign in to access this content
Sign InAbbott's guidance hike highlights a period of stability for the healthcare sector relative to more volatile tech peers. Per market data, major medical device manufacturers have maintained steady growth trajectories this quarter. ManpowerGroup’s revenue beat further underscores global labor market resilience, aligning with US employment data which showed initial jobless claims falling to 215,000 for the week ending July 9, 2026.
In the equity markets, ABT shares closed at $89.27 on July 15, 2026, after reaching a session high of $89.88. Investors are now weighing these earnings against the broader macroeconomic backdrop, including the Federal Reserve's Monetary Policy Report released on July 10, 2026, which remains a critical factor for future corporate borrowing costs and capital expenditure plans.